# Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers

> **NCT01931761** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 6 (actual)

## Conditions studied

- Solid Tumours

## Interventions

- **DRUG:** [C14] selumetinib (oral)

## Key facts

- **NCT ID:** NCT01931761
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2015-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01931761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01931761, "Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01931761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*